The efficacy of dual BRAF and meiotic chromosome‐axis‐associated kinase (MEK) inhibitors has been evaluated in previously treated and untreated patients with BRAF V600E‐mutant metastatic NSCLC, in whom it achieved overall response rates of 63%–64% and complete response rates of 4%–6%.3, 4. This evidence concerns the gene BRAF and non-small cell lung carcinoma.